Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes.

Summary: For patients with type 2 diabetes and high heart risk, standard insulin treatment might not be enough to protect the heart. A new study looked at 163 patients to see if modern drugs work better. The researchers found that combining two newer medications—Liraglutide and Empagliflozin—worked significantly better than insulin alone. This "power couple" combination drastically lowered heart stress markers and improved the body's ability to produce energy and fight inflammation. While each drug helped individually, taking them together provided the strongest shield for the heart.